Abstract P4-12-04: Cost-effectiveness analysis of locally advanced estrogen receptor-positive, HER-2 negative breast cancer care using a tailored treatment approach in Brazil

Her 2

Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China

Clinical Drug Investigation ◽

10.1007/s40261-019-00842-0 ◽

2019 ◽

Vol 40 (1) ◽

pp. 25-32 ◽

Cited By ~ 2

Author(s):

Xiaoxia Wei ◽

Hong Sun ◽

Jie Zhuang ◽

Xiuhua Weng ◽

Bin Zheng ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Cost Effectiveness Analysis ◽

Pharmacogenetic Testing ◽

Effectiveness Analysis ◽

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 567-567 ◽

Cited By ~ 3

Author(s):

Klazien Matter-Walstra ◽

Matthias Schwenkglenks ◽

Peter Brauchli ◽

Dirk Klingbiel ◽

Konstantin J. Dedes

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

PCN189 COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN

Value in Health ◽

10.1016/j.jval.2019.09.385 ◽

2019 ◽

Vol 22 ◽

pp. S472

Author(s):

S. Taheri ◽

Z. Karimi Majd ◽

S. Rezaei ◽

N. Yousefi ◽

F. Peiravian

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Cost Effectiveness Analysis ◽

Advanced Breast ◽

Effectiveness Analysis ◽

A cost-effectiveness analysis of axillary node dissection in postmenopausal woman with estrogen receptor–positive breast cancer and clinically negative axillary nodes

Surgery ◽

10.1016/s0039-6060(99)70046-2 ◽

1999 ◽

Vol 126 (5) ◽

pp. 987-988

Author(s):

Edward M. Copeland

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Postmenopausal Woman ◽

Cost Effectiveness ◽

Axillary Node ◽

Axillary Node Dissection ◽

Node Dissection ◽

Effectiveness Analysis ◽

A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor–positive breast cancer and clinically negative axillary nodes

Surgery ◽

10.1016/s0039-6060(99)70100-5 ◽

1999 ◽

Vol 126 (3) ◽

pp. 568-576 ◽

Cited By ~ 16

Author(s):

Richard K. Orr ◽

Nananda F. Col ◽

Karen M. Kuntz

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Axillary Node ◽

Axillary Node Dissection ◽

Node Dissection ◽

Effectiveness Analysis ◽

Abstract PS12-15: Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2- BC)

10.1158/1538-7445.sabcs20-ps12-15 ◽

2021 ◽

Author(s):

Oneeb Majid ◽

Jianjun Alan Xiao ◽

Tarek Sahmoud ◽

Sanae Yasuda ◽

Lisa Cantagallo ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Locally Advanced ◽

Lifetime Cost-Effectiveness of Adjuvant External Beam Whole Breast Irradiation (EBWBI) in Estrogen Receptor Positive (ER+) Early-Stage Breast Cancer (ESBC) Women: Cardiotoxicity Consideration

Value in Health ◽

10.1016/j.jval.2018.04.209 ◽

2018 ◽

Vol 21 ◽

pp. S33

Author(s):

KO Ezendu ◽

V Diaby ◽

AA Ali

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Early Stage ◽

Lifetime Cost ◽

Early Stage Breast Cancer ◽

External Beam ◽

Whole Breast Irradiation ◽

Breast Irradiation ◽

Abstract 4415: Differential effects of biochanin A on cell proliferation and ROS-dependent pathways in estrogen receptor positive and HER-2 positive breast cancer cells.

10.1158/1538-7445.am2013-4415 ◽

2013 ◽

Author(s):

Lindsy Dickerson ◽

Vikas Sehdev ◽

Pamela L. Crowell ◽

James C.K. Lai ◽

Alok Bhushan

Keyword(s):

Breast Cancer ◽

Cell Proliferation ◽

Estrogen Receptor ◽

Cancer Cells ◽

Breast Cancer Cells ◽

Biochanin A ◽

Differential Effects ◽

Her 2 ◽

Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)

10.1158/1538-7445.sabcs14-p5-19-06 ◽

2015 ◽

Author(s):

Hans Tesch ◽

Oliver J Stoetzer ◽

Thomas Decker ◽

Christian M Kurbacher ◽

Romy Neumeister ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Efficacy Analysis ◽

Phase Iiib ◽

Abstract P3-05-16: The effect of HER-2/neu inhibition on prolonging clinical benefit with fulvestrant treatment for metastatic estrogen receptor positive breast cancer patients treated with trastuzumab

10.1158/1538-7445.sabcs14-p3-05-16 ◽

2015 ◽

Cited By ~ 1

Author(s):

Mahmoud Charif ◽

Elyse E Lower ◽

Diane Kennedy ◽

Harriet Kumar ◽

Shugufta Khan ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cancer Patients ◽

Clinical Benefit ◽

Breast Cancer Patients ◽

Her 2 ◽